title: The heparin target organ--the endothelium. Studies in a rat model.
abstract: Plasma levels of the antithrombotic drug heparin, as estimated by coagulation tests, are a poor indicator of antithrombotic effectiveness. The interaction of heparin with endothelium is a poorly studied but important factor in the clinical activity of heparin. This study describes the interaction of heparin with endothelium, following intragastric administration. The concentrations of heparin in endothelium and plasma were determined by gel electrophoresis following administration of heparin to rats by various routes. Heparin concentrations in endothelium versus plasma were approximately 100 times greater following intravenous or ex vivo administration and more than 1000 times greater when administered by intrapulmonary, subcutaneous, intraperitoneal and intragastric routes indicating that the route of administration affects the distribution of the drug. At 2.4 and 6 min after intravenous administration, 88 and 51% respectively of the administered dose was found associated with endothelium. Heparin was rapidly absorbed following intragastric administration and could be detected associated with endothelium at 2.4 min. At 6 min less than 1% of the administered dose was found in plasma, and 45% was associated with endothelium. These results show that endothelium is the main site of heparin distribution. Heparins could also be detected in cellular and pericellular fractions of cultured porcine aortic endothelial cells when 125I-heparin was added to medium. Bound radioactivity was released to medium from both cellular and pericellular fractions suggesting that heparin taken up by endothelium can be released. Intragastric administration of heparin and dextran sulphates significantly prevented thrombus formation in a rat model of thrombosis without significant changes in activated partial thromboplastin times.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Veterinary Physiological Sciences, University of Saskatchewan, Saskatoon, Canada.
authors.forename: L M
authors.initials: LM
authors.lastname: Hiebert
authors.forename: S M
authors.initials: SM
authors.lastname: Wice
authors.forename: N M
authors.initials: NM
authors.lastname: McDuffie
authors.forename: L B
authors.initials: LB
authors.lastname: Jaques
mesh_terms: D000818:Animals; D004727:Endothelium / Q000378:metabolism*; D006493:Heparin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D007262:Infusions, Intravenous; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008954:Models, Biological; D051381:Rats; D013997:Time Factors
chemical_list: D006493:Heparin